We describe a case of ETV6‐MECOM fusion‐positive refractory AML, where molecular analysis and in vitro high throughput drug screening identified a tolerable, novel targeted therapy and provided rationale for avoiding what could have been a toxic treatment regimen. This evidence concerns the gene ETV6 and acute myeloid leukemia.